Cowen And Company, LLC Avadel Pharmaceuticals PLC Transaction History

Cowen And Company, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$9.64 - $14.59 $15.8 Million - $24 Million	1,642,347 New	1,642,347 $23.2 Million
Q3 2023 Nov 09, 2023	SELL	$10.3 - $15.99 $3.36 Million - $5.21 Million	-325,774 Reduced 12.23%	2,338,302 $24.1 Million
Q2 2023 Aug 07, 2023	SELL	$8.48 - $16.48 $9.06 Million - $17.6 Million	-1,068,702 Reduced 28.63%	2,664,076 $43.9 Million
Q4 2021 Feb 14, 2022	BUY	$7.34 - $11.18 $8.86 Million - $13.5 Million	1,207,326 Added 47.81%	3,732,778 $30.2 Million
Q3 2021 Nov 12, 2021	BUY	$6.49 - $9.91 $193,914 - $296,100	29,879 Added 1.2%	2,525,452 $24.7 Million
Q1 2021 May 04, 2021	BUY	$6.61 - $10.07 $3.99 Million - $6.08 Million	603,530 Added 31.9%	2,495,573 $22.6 Million
Q4 2020 Feb 08, 2021	SELL	$5.03 - $7.95 $70,153 - $110,878	-13,947 Reduced 0.73%	1,892,043 $12.6 Million
Q3 2020 Nov 03, 2020	SELL	$5.02 - $8.98 $7,600 - $13,595	-1,514 Reduced 0.08%	1,905,990 $9.61 Million
Q2 2020 Aug 13, 2020	BUY	$7.25 - $11.75 $2.83 Million - $4.58 Million	390,208 Added 25.72%	1,907,504 $15.4 Million
Q1 2020 May 11, 2020	BUY	$4.06 - $10.64 $6.16 Million - $16.1 Million	1,517,296 New	1,517,296 $10.8 Million

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $478M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Cowen And Company, LLC, based on Form 13F filings with the SEC.

Stay updated on Cowen And Company, LLC with notifications on news.